Supplementary Table 1, Supplementary Figures 1-4 from A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations

Supplementary Table 1. Pharmacokinetic Parameters of ASP8273 from Patients in Dose-Escalation Cohort (PKAS) ; Supplementary Figure 1. Study design; Supplementary Figure 2. Quantitative change in EGFR cfDNA from baseline to Cycle 2 in escalating dose levels of ASP8273; Supplementary Figure 3. Changes in Levels of Mutant EGFR cfDNA (Activating or T790M) in Patients after One Cycle of Treatment with ASP8273 by Best Overall Response; Supplementary Figure 4. Identification of EGFR activating mutations, EGFR T790M and EGFR C797S in cfDNA from patients with Emergence of acquired resistance to ASP8273.